The ANA values the participation of our corporate partners and is supportive of the role that members of this community continue to play in our efforts to provide neurologists & neuroscientists with quality educational programs. These symposia are not part of the ANA official educational program and the sessions and content are not endorsed by ANA.
Session Title: Insights into Using Dual Antiplatelet Therapy in Patients with Acute Ischemic Stroke and Transient Ischemic Attack**
Session Description: There is a substantial risk for recurrent stroke in the early period after an acute ischemic stroke or transient ischemic attack (TIA). Aspirin (ASA) has been a fundamental preventive therapy in these patients; however, residual risk remains despite ASA monotherapy. The CHANCE and POINT trials, albeit with distinct differences, have demonstrated the effectiveness of the timely and short-term addition of clopidogrel to ASA. However, patients with CYP2C19 loss-of-function (LOF) alleles are poor metabolizers of clopidogrel and often have a suboptimal response to dual antiplatelet therapy (DAPT) when clopidogrel is added to ASA. In the THALES trial, more potent antiplatelet therapy with the P2Y12 inhibitor ticagrelor, in combination with ASA, has demonstrated a reduction in risk of recurrent stroke in patients with mild-to-moderate acute ischemic stroke or high-risk TIA. More recent insights from the THALES trial have assessed the effectiveness and safety of dual therapy with ticagrelor in reducing disabling stroke and disability after recurrent stroke, as well as outcomes in patients with and without ipsilateral atherosclerosis stenosis. Platelet reactivity has been compared between clopidogrel plus ASA and ticagrelor plus ASA in patients with TIA or minor stroke, and an ongoing trial is investigating clinical outcomes of TIA or minor stroke patients who are CYP2C19 LOF allele carriers and who are receiving either DAPT with ASA plus clopidogrel or ASA plus ticagrelor. In this program, experts in the management of stroke with antiplatelet therapy will interpret clinical trial evidence and identify patients for use of DAPT. A panel discussion will follow, with a focus on overcoming barriers to timely and successful implementation of DAPT.
Session Date: Saturday, October 16th, 2021
Session Time: 3:30 PM – 4:30 PM EDT
Sponsored By: Voxmedia; Commercial Supporter: AstraZeneca Pharmaceuticals
- S. Claiborne Johnston, MD, PhD; University of Texas at Austin
- Gregory Albers, MD; Stanford University School of Medicine
- Brett Cucchiara, MD; Hospital of the University of Pennsylvania
- Deborah Diercks, MD; University of Texas Southwestern
Session Title: Exploring the Utility of Whole-Genome Sequencing for the Diagnosis and Management of White Matter Disorders**
Session Description: This session will provide an overview of the current state of WGS and transcriptomics for neurological disorders and discuss the impact results can have on clinical management and long-term outcomes. The presenters will review interim data from an observational study that implemented WGS as a first-tier test in patients with leukodystrophy and provide an overview of the next phase of that study which will evaluate clinical utility up to six months after results.
Session Date: Monday, October 18th, 2021
Session Time: 7:45 PM – 8:45 PM EDT
Sponsored By: Illumina
- Kayla J. Muirhead, MS, LCGC; Children’s Hospital of Philadelphia
- Holly Snyder, MS, LCGC; Illumina, Inc.
- Dr. Ryan Taft, PhD; Illumina, Inc.
Session Title: New Hope for Early-Stage Alzheimer's Disease: Can We Modify the Disease Pathway by Targeting Amyloid-β?**
Session Description: The objective of this activity series is to improve neurologists’ knowledge and competence in evaluating the rationale behind selectively targeting neurotoxic soluble amyloid-β oligomers in early-stage AD, assessing the latest evidence on the efficacy and safety of emerging late-stage anti-amyloid-β immunotherapies and proposing a patient-centered approach that will maximize the benefits of these emerging therapies.
Session Date: Tuesday, October 19th, 2021
Session Time: 8:30 AM – 9:30 AM EDT
Sponsored By: Answers in CME (This activity is supported by an educational grant from Biogen)
- Marwan N. Sabbagh, MD; Cleveland Clinic
- James E. Galvin, MD, MPH; University of Miami Miller School of Medicine
- Lueva Demps; Alzheimer's Caregiver
Session Title: Once-Daily ONGENTYS (opicapone) Capsules: An Early Levodopa/Carbidopa Partner for OFF Time in Parkinson's Disease**
Session Date: Tuesday, October 19th, 2021
Session Time: 4:30 PM – 5:30 PM EDT
Sponsored By: Neurocrine Biosciences
- Dr. Fernando L. Pagan, MD; Medstar Georgetown University Hospital
- Brooke McCausland, MA; Neurocrine Biosciences
**This session is not available for AMA PRA Category I Credit(s)™, however, the sponsor may be accrediting this event independently. Please check the website for details closer to the date of the event.